Tag Archives: Novavax

The SVP & GC of Novavax is Exercising Options

Today it was reported that the SVP & GC of Novavax (NVAX – Research Report), John Herrmann, exercised options to sell 12,961 NVAX shares at $26.18 a share, for a total transaction value of $640.8K. Following John Herrmann’s last NVAX

Analysts’ Top Healthcare Picks: Novavax (NVAX), Halozyme (HALO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX – Research Report), Halozyme (HALO – Research Report) and Bluebird Bio (BLUE – Research Report) with bullish sentiments. Novavax (NVAX)

H.C. Wainwright Reaffirms Their Buy Rating on Novavax (NVAX)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax (NVAX – Research Report) on April 30 and set a price target of $33.00. The company’s shares closed last Friday at $17.33. According to TipRanks.com, Bernardino is a 5-star

Ladenburg Thalmann & Co. Believes Novavax (NASDAQ: NVAX) Still Has Room to Grow

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Novavax (NVAX – Research Report), with a price target of $28.00. The company’s shares closed last Wednesday at $17.18, close to its 52-week

Novavax (NVAX) Received its Third Buy in a Row

After Ladenburg Thalmann & Co. and H.C. Wainwright gave Novavax (NASDAQ: NVAX) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Kevin DeGeeter maintained a Buy rating on Novavax today and set a price

Analysts Are Bullish on These Healthcare Stocks: Novavax (NVAX), Madrigal Pharmaceuticals (MDGL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX – Research Report), Madrigal Pharmaceuticals (MDGL – Research Report) and CareDx (CDNA – Research Report) with bullish sentiments. Novavax (NVAX)